TP53 and central nervous system cancer: The treatment of gliomas has entered the era of molecular profiling, with pivotal genomic studies highlighting the significance of molecular markers such as IDH mutations, 1p/19q codeletion, MGMT promoter methylation, ATRX mutations, TERT promoter mutations, PTEN mutations, and TP53 mutations and so on.